Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BCAL Diagnostics Limited ( (AU:BDX) ) has issued an announcement.
BCAL Diagnostics Limited has entered into a strategic partnership with ClearNote Health, granting BCAL exclusive distribution rights for ClearNote’s Avantect Pancreatic and Avantect Ovarian tests in Australia and New Zealand. This agreement, initially set for two years with potential extensions, positions BCAL to enhance its market presence in the early detection cancer test industry, potentially impacting its operations and stakeholder interests positively.
More about BCAL Diagnostics Limited
Average Trading Volume: 187,991
Technical Sentiment Signal: Hold
Current Market Cap: A$25.25M
See more data about BDX stock on TipRanks’ Stock Analysis page.